Pure small cell carcinoma of the prostate

Clinical Oncology

Volumn 9, Issue 6, 1997, Pages 412-414

  Sandhu, S S ^a   Denton, A ^a   Jarmulowicz, M ^a   Pigott, K ^a   Kaisary, A V ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Anaplastic; Neuroendocrine; Prostate cancer; Small cell

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; CALCITONIN; CYPROTERONE ACETATE; ENOLASE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANAPLASTIC CARCINOMA; ARTICLE; CASE REPORT; CLINICAL FEATURE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; NEUROENDOCRINE TUMOR; ORAL DRUG ADMINISTRATION; PATHOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; SMALL CELL CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031457188     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(97)80142-2     Document Type: Article

References (16)

1. Abrahamsson PA, Wadstrom LB, Alumets J, et al. Peptide hormone and serotonin immunoreactive cell in normal and hyperplastic prostate glands. Path Res Pract 1986;181:675-83.
2. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23:287-96.
3. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells: a new prognostic parameter in prostatic carcinoma. Br J Urol 1991;68:258-62.
4. Allen FJ, Van Velden DJ, Heyns CF. Are neuroendocrine cells of practical value as an independant prognostic parameter in prostate cancer? Br J Urol 1995;75:751-4.
5. Bleichner JC, Chun B, Klappenbach S. Pure small cell carcinoma of the prostate with fatal liver metastasis. Arch Pathol Lab Med 1986;110:1041-4.
6. Ro JY, Tetu B, Ayala AG, et al. Small cell carcinoma of the prostate: immunohistochemical and electron microscopic studies of 18 cases. Cancer 1987;59:977-82.
7. Turbat-Herrera BA, Herrera G, Gore I, et al. Neuroendocrine differentiation in prostatic carcinoma. Arch Pathol Lab Med 1988;112:1100-5.
8. Oesterling JE, Hauzer CG, Farrow GM. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J Urol 1992; 147:804-7.
9. Abrahamson PA, Falkmer S, Falt K, et al. The course of neuroenducrine differentiation in prostatic carcinoma. Path Res Pract 1989;185:373-80.
10. Cussenot O, Villette JM, Valeri A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996;155:1340-3.
11. Bonkhoff H, Stein U, Remberger K. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate. Virchows Archiv A Pathol Anat Histopathol 1993;423:291-4.
12. Bolton DM, Chiu ST, Clarke S, et al. Pure small cell carcinoma of the prostate: unusual modes of presentation. Aust NZ J Surg 1994;64:91-4.
13. Christopher ME, Seftel AD, Sorenson K, et al. Small cell carcinoma of the genitourinary tract: an immunohistochemical, electron microscopic and clinicopathological study. J Urol 1992;146:382-8.
14. Moore SR, Reinberg Y, Zhang G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 1992;39:411-6.
15. Amato RJ, Logothetis CJ, Hallinan R, et al. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147:935-7.
16. Tetu B, Ro JY, Ayala AG, et al. Small cell carcinoma of the prostate: a clinicopamological study of 20 cases. Cancer 1987;59:1803-9.